公开(公告)号：US07833546B2

公开(公告)日：2010-11-16

申请号：US10502648

申请日：2003-01-30

申请人： Hans-Ulrich Petereit ,  Thomas Suefke ,  Christian Meier ,  Michael Schnabel ,  Ingrid Blesing ,  Stefan Grimm

发明人： Hans-Ulrich Petereit ,  Thomas Suefke ,  Christian Meier ,  Michael Schnabel ,  Ingrid Blesing ,  Stefan Grimm

IPC分类号： A61K9/20 ,  A61K9/22 ,  A61K9/48 ,  A61K9/14 ,  A61F13/00

CPC分类号： A61K9/5026 ,  A61K9/2846 ,  Y02A50/473

摘要： The invention relates to a method for producing a pharmaceutical dosage form as tablets, pellets and/or in the form of an active ingredient-containing matrix, whereby the tablets, pellets and/or active ingredient-containing matrix contain a pharmaceutical active ingredient and a copolymer serving as a coating agent and/or binding agent, and optionally contain a core and pharmaceutically common additives. According to the invention, the copolymer, the pharmaceutical active ingredient, the optionally present core and/or the pharmaceutically common additives are processed using known techniques by melting, injection molding, extrusion, wet granulation, casting, dipping, spreading out, spraying on, or pressing to form tablets, pellets and/or an active ingredient-containing matrix. The inventive method is characterized in that a copolymer is used that consists of 20 to 34 wt. % methacrylic acid, 20 to 69 wt. % methylacrylate and 0 to 40 wt. % ethylacrylate and, optionally, of 0 to 10 wt. % of additional vinylically copolymerizable monomers with the provision that the glass transition temperature of the copolymer is no higher than 60° C. according to ISO 11357-2, Item 3.3.3. The invention also relates to the pharmaceutical dosage form produced according to this method, said copolymer and the use thereof.

摘要翻译： 本发明涉及用于制备药物剂型作为片剂，丸粒和/或含有活性成分的基质形式的方法，由此所述片剂，丸剂和/或含活性成分的基质含有药物活性成分和 共聚物作为包衣剂和/或粘合剂，并且任选地含有核心和药学上常用的添加剂。 根据本发明，共聚物，药物活性成分，任选存在的核心和/或药学上常用的添加剂使用已知技术通过熔融，注射成型，挤出，湿法制粒，浇铸，浸渍，扩散，喷涂， 或压制以形成片剂，丸剂和/或含活性成分的基质。 本发明的方法的特征在于使用由20〜34重量％ ％甲基丙烯酸，20〜69重量％ ％甲基丙烯酸酯和0至40wt。 ％丙烯酸乙酯和任选地0至10wt。 ％的额外的乙烯基共聚单体，其规定，根据ISO 11357-2，项目3.3.3，共聚物的玻璃化转变温度不高于60℃。 本发明还涉及根据该方法生产的药物剂型，所述共聚物及其用途。

公开(公告)号：US20050079216A1

公开(公告)日：2005-04-14

申请号：US10502648

申请日：2003-01-30

申请人： Hans-Ulrich Petereit ,  Thomas Suefke ,  Christian Meier ,  Michael Schnabel ,  Ingrid Blesing ,  Stefan Grimm

发明人： Hans-Ulrich Petereit ,  Thomas Suefke ,  Christian Meier ,  Michael Schnabel ,  Ingrid Blesing ,  Stefan Grimm

IPC分类号： A61J3/06 ,  A61K9/02 ,  A61K9/08 ,  A61K9/20 ,  A61K9/28 ,  A61K9/32 ,  A61K9/48 ,  A61K9/50 ,  A61K9/52 ,  A61K31/49 ,  A61K47/20 ,  A61K47/32 ,  A61P9/06 ,  A61K9/14

CPC分类号： A61K9/5026 ,  A61K9/2846 ,  Y02A50/473

摘要： The invention relates to a method for producing a pharmaceutical dosage form as tablets, pellets and/or in the form of an active ingredient-containing matrix, whereby the tablets, pellets and/or active ingredient-containing matrix contain a pharmaceutical active ingredient and a copolymer serving as a coating agent and/or binding agent, and optionally contain a core and pharmaceutically common additives. According to the invention, the copolymer, the pharmaceutical active ingredient, the optionally present core and/or the pharmaceutically common additives are processed using known techniques by melting, injection molding, extrusion, wet granulation, casting, dipping, spreading out, spraying on, or pressing to form tablets, pellets and/or an active ingredient-containing matrix. The inventive method is characterized in that a copolymer is used that consists of 20 to 34 wt. % methacrylic acid, 20 to 69 wt. % methylacrylate and 0 to 40 wt. % ethylacrylate and, optionally, of 0 to 10 wt. % of additional vinylically copolymerizable monomers with the provision that the glass transition temperature of the copolymer is no higher than 60° C. according to ISO 11357-2, Item 3.3.3. The invention also relates to the pharmaceutical dosage form produced according to this method, said copolymer and the use thereof.

摘要翻译： 本发明涉及用于制备药物剂型作为片剂，丸粒和/或含有活性成分的基质形式的方法，由此所述片剂，丸剂和/或含活性成分的基质含有药物活性成分和 共聚物作为包衣剂和/或粘合剂，并且任选地含有核心和药学上常用的添加剂。 根据本发明，共聚物，药物活性成分，任选存在的核心和/或药学上常用的添加剂使用已知技术通过熔融，注射成型，挤出，湿法制粒，浇铸，浸渍，扩散，喷涂， 或压制以形成片剂，丸剂和/或含活性成分的基质。 本发明的方法的特征在于使用由20〜34重量％ ％甲基丙烯酸，20〜69重量％ ％甲基丙烯酸酯和0至40wt。 ％丙烯酸乙酯和任选地0至10wt。 ％的额外的乙烯基共聚单体，其规定，根据ISO 11357-2，项目3.3.3，共聚物的玻璃化转变温度不高于60℃。 本发明还涉及根据该方法生产的药物剂型，所述共聚物及其用途。